subjects (CNTs). PBMCs, isolated from 9 among the SSc patients, were cultured on fibronectin-coated plates [5] . The non-adherent cells were removed and after 8 days (t8) of culture (standardized time), the adherent spindle shaped cells were lifted through incubation in 0.05% EDTA (ice-cold). Fibrocyte identification (at both t0, t8), was performed by FACS, using anti-CD45, anti-COL I, anti-CXCR4 and anti-HLA-DR monoclonal antibodies. Results: FACS analysis revealed that, at basal time (t0), among the CD45+ cells, the percentage of fibrocytes, identified as triple positive (CD45+, COL I+, CXCR4+) was 1.0±1.2% in SSc patients and 0.4±0.3% in healthy subjects (CNTs). In addition, the HLA-DR expression on fibrocytes in both SSc patients and CNTs showed low values (22.1±21.1% and 7.1±6.1%, respectively). After 8 days (t8) of culture, fibrocytes presented adherent and spindle shaped morphology. Interestingly, the FACS analysis at t8 of culture, demonstrated that the percentage of SSc fibrocytes CD45+, COL I+, CXCR4+ increased up to 52.8±27.1%, compared to basal time (t0), as well as strongly increasing the HLA-DR+ expression (90.1±22.7%). Conclusions: Fibrocytes isolated from CPCs of SSc patients were confirmed to express CD45, COL I and CXCR4 molecules, but in very low percentage at the beginning. Already after 8 days of culture in proper conditions, the percentage of differentiated fibrocytes (CD45+, COL I+ and CXCR4+) from SSc patients, increased up to 50 times and the HLA-DR expression increased up to 68%. Background: Scleroderma (SSc) is a connective tissue disease characterized by immunomediated inflammation and fibrosis. The presence of autoantibodies against chromosome associate proteins,such as anti-centromere proteins and anti-topoisomerase I, was observed in SSc patients, however genotoxic events have never been evaluated (2). Objectives: To assess the presence of aneuploidia, micronuclei (MN) and other chromosomal aberrations in peripheral lymphocytes in a bleomycin (BLM)-induced scleroderma mouse model. Methods: BALB/c mice (n=20 per condition) were injected subcutaneously daily with BLM 2mg/kg or PBS (control) for 14 days. Urine was collected weekly and proteinuria was measured. At day 15 mice were sacrificed and organs harvested for histological analysis. The MN assay was performed on cultured peripheral lymphocytes isolated from mice spleens. Cells were treated with cytochalasin B (10 μg/ml) for 24 h and a minimum of 1000 binucleated cells/mouse were scored following the criteria of Fenech (1). The antikinetochore (CREST) staining was used to determine the origin of MN observed. Results: In BLM treated mice was observed huge perivascular lung fibrosis and significant skin involvement. 17 out of 20 mice developed acute renal involvement with mean proteinuria levels of 730±48 mg/dl. In comparison with the control mice, a significant increase in MN number was observed in BLM treated mice (57,8±4,4 vs 6,3±0,6, p<0.05). CREST staining was higher in MN derived from BLM treated mice (16,4±1,1 vs 3,7±0,7, p<0,025), indicating that in this group lymphocyte MN arised mainly from lagging chromosomes. In addition, an increased frequency of ring chromosome was observed in mice with greater skin fibrosis and renal involvement.A correlation between the presence of CREST stained MN and disease severity parameters as renal failure, lung and skin fibrosis was observed (respectively R=0,4095; R=0,7507 and R=0,9471) . Conclusions: This study provides experimental evidence that significant chromosomal aberrations seem to be related to the severity of disease in a mouse model of SSc. Further investigations on lymphocytes obtained from SSc patients could be matched with results observed in mouse model to confirm the relationship between severity of the disease and chromosomal abnormalities. Background: In the damaged tissue of systemic sclerosis (SSc) patients, the presence of immune inflammatory infiltrate, characterized by T-cells and macrophages, represents an important early pathological event in the fibrotic process (1). In the macrophage population, the alternatively activated (M2) macrophages were observed in both peripheral blood and damage tissues of SSc patients and they participate in the fibrotic process exerting profibrotic effects, primarily by the production and release of transforming growth factor β1 (TGFβ1) (1,2). These cells are characterized by the expression of specific phenotype markers, such as mannose receptor (CD206) and scavenger receptors (CD204 and CD163), and the production of specific chemokines (i.e. macrophage derived chemokine, CCL-22) (3). Endothelin-1 (ET1) plays an important role in the fibrotic process of SSc by inducing the profibrotic phenotype in endothelial cells and fibroblasts (4). Objectives: To evaluate the ability of ET1 to upregulate the profibrotic gene expression profile characterizing the M2 macrophages in cultured monocytes/macrophages isolated from SSc patients. Methods: Human monocytes were isolated from peripheral blood mononuclear cells of 4 SSc patients (mean age 59±11years, 2 females and 2 males, treated with vasodilator drugs) using a monocyte isolation kit. Cultured cells were maintained in RPMI growth medium for 24hrs and then treated with ET1 (100nM) for 6 days or treated for 1hr with ET receptor antagonist (ET A/B RA, bosentan 10μM) before stimulation with ET1. Cultured cells maintained in RPMI growth medium were used as untreated cells. Gene and protein expression of M2 phenotype markers and TGFβ1 were evaluated by quantitative real-time polymerase chain reaction (qRT-PCR) and Western blotting (WB). Statistical analysis was carried out using a Mann-Whitney non-parametric test. 
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Background: The majority of Scleroderma (SSc) patients have gastrointestinal involvement. Motility is usually compromised but few studies address permeability changes in the intestinal wall. ASCA is an antibody direct against mannan in the cell wall of Saccharomyces cerevisiae, the baker's yeast that is found mainly when the small bowel is involved in Chron's disease. Nowadays ASCA is regarded more as a marker of increased gastrointestinal permeability than as a serological autoimmune marker of intestinal inflammatory disease. ASCA levels (anti-Sacharomyces Cerevisae antibodies) are associated with increased intestinal permeability. Objectives: At present we study the presence of ASCA in the serum of SSc patients aiming to know if there is increased intestinal permeability in this disease and if this is related to any clinical, demographic and treatment data. Methods: Seventy four SSc patients and 57 healthy controls were studied for ASCA (IgG and IgA) positivity by ELISA. ASCA positivity was associated with demographic, clinical, severity index (Medsger score) and serological data in SSc patients. Results: ASCA IgG levels were high in 26/74 (43.7%) patients from SSc group and 1/57 (5.2%) of controls (p<0.001); IgA ASCA was high in 12/74 (16.2%) from SSc group and 3/57 (1.7%) of controls (p=0.006). In univariated analysis IgG ASCA high levels associated positively with African background (p<0.0001) and negatively with anticentromere antibodies (p=0.013); ASCA IgA had a negative association with Medsger score (p=0.05). In multivariated analysis IgG ASCA associated independently only with African ethnic background. Conclusions: Positivity for IgG and IgA ASCA are higher among scleroderma patients than controls. African descendants have more positivity for IgG ASCA and ASCA IgA were less commonly seen in patients with more severe disease. Background: In young organisms intensive bone turnover is observed and it allows the skeleton to achieve proper side, shape and weight of bones. It is extremely important to assess the influence on various drugs on growing bones. Fenspiride is registered for therapy of acute and chronic respiratory tract infections in children and adolescence. It decreases the synthesis of proinflammatory cytokines, blocks H1 receptors and has bronchodilatotory properties. Objectives: The aim of the study was to assess the influence of long-term administration of fenspiride on bone mineral density and selected markers on bone turnover in young growing rats. Methods: The experiment was carried out on18 young (8-week-old) male Wistar rats receiving standard diet containing 1.2% of calcium ans 0.7% of phosphate. Rats were randomly assigned to one of two groups (9 animals in each group): group F -rats receiving fespiride (15 mg /kg) in saline solution (4ml/kg), and group C (control group) -rats receiving saline solution (4ml/kg). Saline solution and fenspiride were given intragastrically once daily for 90 days (from day 3 to day 92). On day 1 and 93 blood samples for serum isolation were collected. Markers of bone turnover were assessed with commercial ELISA kits according to producers' instruction. Bone mineral density (BMD) was measured by dual-energy X-ray absorptiometry (DXA) with Hologic DXA equipment (Hologic Dicovery W 81507) using a small animal software. The experiment was performed with the approval of the First Local Ethics Committee for Experiments on Animals in Wroclaw. Results: On Day 1 there was no difference in age and body weight between groups. On Day 1 no difference in total body bone mineral density (BMD) (0.160±0.0065 g/cm 2 vs. 0.1608±0.0056 g/cm 2 ), lower limbs BMD (0.232±0.0267 g/cm 2 vs. 0.2274±0.0314 g/cm 2 ), serum levels of bone turnover markers (osteocalcin: 1000.921±109.0705 pg/ml vs. 952.5777±178.5306 pg/ml; bCTX: 280.089±54.4298 pg/ml vs. 292.8979±116.0042 pg/ml; osteoprotegerin: 3.5±0.6338 pg/ml vs. 3.7963±0.6894 pg/ml; RANKL: 0.167±0.4099 pg/ml vs. 1.0218±1.2717 pg/ml) was detected. On Day 93 there was no difference in body weight, total body BMD and lower limbs (0.212±0.0104 g/cm 2 vs. 0.2035±0.0242 g/cm 2 ; 0.264±0.0159 g/cm 2 vs. 0.2520±0.0271 g/cm 2 , respectivelly) between groups. On Day 93 no difference between groups in serum bone turnover markes was detected (OC: 422.758±92.3316 pg/ml vs. 429.2071±83.0520 pg/ml; bCTX: 307.748±77.6733 pg/ml vs. 285.3486±79.16334; OPG: 5.466±0.7815 pg/ml vs. 5.3520±1.6458 pg/ml; RANKL:0.647±0.8457 pg/ml vs. 0.5630±0.8608 pg/ml). Conclusions: Long-term administration of fenspiride has no negative impact on bone mineral density and bone turnover in young growing rats
